Hussman Strategic Advisors Inc. Invests $2.61 Million in iRhythm Technologies $IRTC

Hussman Strategic Advisors Inc. acquired a new position in shares of iRhythm Technologies (NASDAQ:IRTC) during the fourth quarter, HoldingsChannel reports. The firm acquired 14,700 shares of the company’s stock, valued at approximately $2,608,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Federated Hermes Inc. raised its holdings in shares of iRhythm Technologies by 45.4% in the third quarter. Federated Hermes Inc. now owns 70,401 shares of the company’s stock valued at $12,108,000 after purchasing an additional 21,977 shares during the last quarter. Victory Capital Management Inc. raised its holdings in shares of iRhythm Technologies by 30.1% in the third quarter. Victory Capital Management Inc. now owns 77,952 shares of the company’s stock valued at $13,407,000 after purchasing an additional 18,053 shares during the last quarter. Cookson Peirce & Co. Inc. raised its holdings in shares of iRhythm Technologies by 105.4% in the third quarter. Cookson Peirce & Co. Inc. now owns 14,524 shares of the company’s stock valued at $2,498,000 after purchasing an additional 7,452 shares during the last quarter. Jain Global LLC purchased a new stake in shares of iRhythm Technologies in the third quarter valued at about $22,547,000. Finally, Tudor Investment Corp ET AL purchased a new stake in shares of iRhythm Technologies in the third quarter valued at about $3,439,800,000.

iRhythm Technologies Stock Performance

NASDAQ IRTC opened at $120.80 on Friday. iRhythm Technologies has a 52-week low of $112.31 and a 52-week high of $212.00. The company has a 50-day simple moving average of $122.93 and a 200 day simple moving average of $154.44. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63. The company has a market capitalization of $3.97 billion, a PE ratio of -140.46 and a beta of 1.33.

iRhythm Technologies (NASDAQ:IRTC) last posted its quarterly earnings data on Thursday, April 30th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.21. The business had revenue of $199.39 million during the quarter, compared to the consensus estimate of $194.11 million. iRhythm Technologies had a negative net margin of 3.53% and a negative return on equity of 10.97%. The firm’s quarterly revenue was up 25.6% compared to the same quarter last year. During the same quarter last year, the company posted ($0.97) earnings per share. On average, research analysts predict that iRhythm Technologies will post -0.16 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on IRTC shares. The Goldman Sachs Group lowered their target price on shares of iRhythm Technologies from $184.00 to $147.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Morgan Stanley restated an “overweight” rating on shares of iRhythm Technologies in a report on Monday, January 12th. Wall Street Zen upgraded shares of iRhythm Technologies from a “hold” rating to a “buy” rating in a report on Sunday. Robert W. Baird decreased their price objective on shares of iRhythm Technologies from $220.00 to $200.00 and set an “outperform” rating for the company in a report on Friday, February 20th. Finally, Needham & Company LLC raised their price objective on shares of iRhythm Technologies from $254.00 to $255.00 and gave the stock a “buy” rating in a report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, iRhythm Technologies has an average rating of “Moderate Buy” and an average target price of $197.77.

Insider Activity

In other iRhythm Technologies news, insider Chad Patterson sold 8,967 shares of the stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $135.42, for a total transaction of $1,214,311.14. Following the completion of the transaction, the insider owned 51,738 shares in the company, valued at $7,006,359.96. This trade represents a 14.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Quentin S. Blackford sold 25,540 shares of the stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $135.42, for a total transaction of $3,458,626.80. Following the transaction, the chief executive officer owned 186,126 shares of the company’s stock, valued at $25,205,182.92. This represents a 12.07% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 94,509 shares of company stock valued at $12,734,195. 1.10% of the stock is currently owned by corporate insiders.

More iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat on revenue and EPS trends: iRhythm reported $199.4M in revenue (up 25.6% YoY) and a loss per share that was smaller than expected, indicating improving unit economics and topline momentum. This supports longer‑term growth expectations. IRTC Q1 results and call (MarketBeat)
• Positive Sentiment: Needham raised its price target slightly to $255 and keeps a “buy” rating, signaling conviction from at least one growth‑oriented shop and providing a bullish anchor for longer‑term upside. Needham raises PT to $255 (Benzinga)
• Neutral Sentiment: Company guidance: iRhythm issued FY2026 revenue guidance (~$875–$885M) roughly in line with consensus, which is steady but not clearly bullish; EPS guidance was not meaningfully changed. Guidance that meets expectations can temper upside momentum. IRTC Q1 financial results press release (GlobeNewswire)
• Neutral Sentiment: Additional context available from the Q1 earnings call transcript and analyst previews/deep dives — useful for investors evaluating margin progression, reimbursement/regulatory updates and AI initiatives but not immediate price catalysts by themselves. Q1 earnings call transcript (Seeking Alpha)
• Negative Sentiment: Analyst price‑target cuts from JPMorgan (PT lowered to $175 from $215) and Wells Fargo (PT lowered to $180 from $200) are exerting immediate downward pressure by reducing visible upside and prompting some investors to trim positions. JPMorgan & Wells Fargo lower PTs (Benzinga)
• Negative Sentiment: Truist and other outlets flagged cuts to targets in their Q1 previews, adding to the sell‑side pushback; persistent negative margins and a negative return on equity keep valuation sensitive to near‑term profitability improvements. Truist cuts PT on IRTC (Yahoo Finance)

iRhythm Technologies Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.